Smartpatient and Novo Nordisk are expanding their digital patient support partnership in Germany, extending their established obesity care program to an additional treatment format. The move builds on a collaboration that began in 2025 and reflects the companies' strategy of adapting digital support services as treatment options and patient needs evolve.
The partnership initially launched with a digital obesity care program designed to support patients throughout their treatment journeys. Earlier in 2026, the companies expanded the collaboration into Type 2 diabetes, broadening the model across metabolic conditions. The latest development further extends the obesity program, allowing patients using different treatment formats to access a consistent digital support experience.
Rather than creating separate support programs for each therapy or format, Smartpatient and Novo Nordisk are focusing on continuity across the patient journey. The approach is designed to provide patients with familiar resources and guidance even as their treatment changes, helping maintain engagement and support over time.
The collaboration also demonstrates how pharmaceutical companies can build digital patient support infrastructure that scales across multiple therapies and conditions. By extending an existing platform instead of introducing separate solutions, the companies aim to create a more connected experience while allowing support programs to evolve alongside new treatment options.
Click here to read the original news story.
